

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics Shares Down ~66% After Co. Terminated ADAPT Study; Co. To Review Possible Strategic Alternatives, Stock To Move To OTC Trading April 23rd

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics Shares Resume Trade, Now Down 66.3%

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics Shares to Resume Trade At 8:30 a.m. EDT

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics Says Trading In Common Stock Will Be Transferred From Nasdaq To OTCQB On Apr. 23, '18

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics To Review Possible Strategic Alternatives

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics Says Co. To Terminate ADAPT Study Based On Interim Results From Phase 3 Trial

Financial news for ARGS dated on 2018-04-19: Argos Therapeutics Shares Halted News Pending

Financial news for ARGS dated on 2018-04-02: Argos Therapeutics Q4 EPS \$(0.38) Beats \$(1.40) Est., Sales \$1.67M Beats \$50K Est.

Financial news for ARGS dated on 2018-02-15: Argos Therapeutics Reports Issuance Of Patent Covering Foundation For Manufacturing Its HIV Immunotherapy

Financial news for ARGS dated on 2018-02-12: A Day Trader's Guide To Fear

Financial news for ARGS dated on 2018-02-07: Argos Therapeutics Shares Down 7.6% On Potential Profit Taking After Stock Rose As Much As 53% Tuesday

Financial news for ARGS dated on 2018-02-06: Argos Therapeutics Shares Up 23.5% After Monday Announcing Receipt Of Option To License PD1 Checkpoint Inhibitors

Financial news for ARGS dated on 2018-02-05: Argos Obtains Option to License PD1 Checkpoint Inhibitors

Financial news for ARGS dated on 2018-01-30: Argos Therapeutics Shares Resume Trade, Pullback From Session Highs, Still Up 35% For Session

Financial news for ARGS dated on 2018-01-30: UPDATE: Argos Therapeutics US PTO Abstract For 'Strain-independent amplification of pathogens and vaccines thereto'

Financial news for ARGS dated on 2018-01-30: Argos Therapeutics Shares Turn Positive, Spike 39%, Halted On Circuit Breaker; Traders Circulating US PTO Doc Showing Co. Won Key US Patent

Financial news for ARGS dated on 2018-01-26: 44 Biggest Movers From Yesterday

Financial news for ARGS dated on 2018-01-24: 40 Biggest Movers From Yesterday

Financial news for ARGS dated on 2018-01-23: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARGS dated on 2018-01-22: 34 Biggest Movers From Friday

Financial news for ARGS dated on 2018-01-19: 28 Stocks Moving In Friday's Mid-Day Session

Financial news for ARGS dated on 2018-01-19: 14 Stocks Moving In Friday's Pre-Market Session

Financial news for ARGS dated on 2018-01-18: Argos Therapeutics Reports 1-For-20 Reverse Stock Split

Financial news for ARGS dated on 2018-01-08: Argos Therapeutics Earlier Announced \$1.5M Sale Of 7.5M Shares Common Stock To Lummy Ltd.

Financial news for ARGS dated on 2017-11-28: Argos Therapeutics Says TKC Properties Successfully Closed Sale Of Facility To A Third Party, Received Cash Proceeds Of ~\$1.8; Co. Raised ~\$6.8M Of Net Proceeds Under ATM Offering

Financial news for ARGS dated on 2017-11-13: Argos Therapeutics Earlier Provided ad Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

Financial news for ARGS dated on 2017-11-12: Argos Therapeutics Provides Update on

Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017

Financial news for ARGs dated on 2017-11-09: Argos Reports Q3 EPS \$(0.10) vs \$(0.20) Est., Sales \$53K vs \$100K Est.

Financial news for ARGs dated on 2017-11-06: Argos Receives \$1.5M Milestone Payment From Lummy

Financial news for ARGs dated on 2017-09-25: Argos Therapeutics Entered Into Satisfaction and Release Agreement With Invetech

Financial news for ARGs dated on 2017-09-12: Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial

Financial news for ARGs dated on 2017-09-06: Argos Therapeutics Reports First Dosing Of HIV Patient With AGS-004 Derived From Latent Viral Reservoir

Financial news for ARGs dated on 2017-08-16: Argos Therapeutics Files For \$4.346M Offering

Financial news for ARGs dated on 2017-08-09: Argos Therapeutics Reports Q2 Loss/Share \$(0.21) vs. \$(0.26) Est., Sales \$69.7K vs. \$100K Est.

Financial news for ARGs dated on 2017-07-26: Argos Announces Immunogenicity Results of AGS-004 in HIV Program, Says Study Achieved Primary Endpoint With All 6 Patients Demonstrating Positive Immune Response

Financial news for ARGs dated on 2017-05-10: Argos Says FDA Agreed With Company's Plan To Continue ADAPT Trial In Accordance With The Current Protocol To 290 Events

Financial news for ARGs dated on 2017-04-19: Mid-Afternoon Market Update: Crude Oil Down Over 4%; CalAmp Shares Surge After Strong Q4 Results

Financial news for ARGs dated on 2017-04-19: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for ARGs dated on 2017-04-19: Mid-Day Market Update: Dow Turns Negative; Argos Therapeutics Shares Spike Higher

Financial news for ARGs dated on 2017-04-19: Mid-Morning Market Update: Markets Mostly Higher; Morgan Stanley Beats Q1 Expectations

Financial news for ARGs dated on 2017-04-19: Argos +79% Premarket @\$0.70; Co Announced Tuesday Interim Results of ADAPT Trial and Decision to Continue Trial

Financial news for ARGs dated on 2017-03-06: 8-K from Argos Therapeutics Shows Entered Into Payoff Letter with Horizon Credit Related to Termination of Venture Loan, Security Deal, Will Pay \$23.1M to Lenders

Financial news for ARGs dated on 2017-02-27: 12 Biggest Mid-Day Losers For Monday

Financial news for ARGs dated on 2017-02-23: Benzinga's Top Upgrades, Downgrades For February 23, 2017

Financial news for ARGs dated on 2017-02-23: Needham Downgrades Argos Therapeutics To Hold

Financial news for ARGs dated on 2017-02-22: Mid-Afternoon Market Update: Microbot Medical Climbs Amid Technology Patent Allowance; Servicesource International Shares Tumble

Financial news for ARGs dated on 2017-02-22: 18 Biggest Mid-Day Losers For Wednesday

Financial news for ARGs dated on 2017-02-22: Mid-Day Market Update: Crude Oil Down 1.5%; Lantheus Shares Surge Following Q4 Results

Financial news for ARGs dated on 2017-02-22: Mid-Morning Market Update: Markets Open Lower; DISH Network Profit Beats Expectations

Financial news for ARGs dated on 2017-02-22: Argos Therapeutics Shares Open for Trade Following Halt

Financial news for ARGs dated on 2017-02-22: Argos Therapeutics to Resume Trading at 8:30 AM ET

Financial news for ARGs dated on 2017-02-22: UPDATE: Argos Says Plans to Leave ADAPT Trial Open While Co. Conducts Ongoing Data Review

Financial news for ARGs dated on 2017-02-22: UPDATE: Argos Says Analyzing Prelim ADAPT Data, Plans to Discuss with FDA

Financial news for ARGs dated on 2017-02-22: Argos Therapeutics Reports Independent Data Monitoring Committee Recommends Discontinuation of ADAPT Phase 3 Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma, Cites Futility

Financial news for ARGs dated on 2017-02-22: Argos Therapeutics Shares Halted News Pending

Financial news for ARGs dated on 2016-12-14: Argos Therapeutics Enters into Strategic Research Agreement with Personalis, Inc.

Financial news for ARGs dated on 2016-11-16: Stifel Healthcare Conference Continues Today

Financial news for ARGs dated on 2016-11-14: Argos Therapeutics Q3 EPS \$(0.32) vs \$(0.35) Est, Revenue \$146.76K vs \$250.00K Est

Financial news for ARGs dated on 2016-11-02: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for ARGs dated on 2016-08-31: 15 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for ARGs dated on 2016-08-25: Pharmstandard INTL SA Buys 67,371 Shares Of Argos Therapeutics @\$4.52/Share -Form 4

Financial news for ARGs dated on 2016-08-10: Argos Therapeutics Reports Q2 EPS \$(0.48) vs. Est. \$(0.43), Rev. \$500K vs. Est. \$200K

Financial news for ARGs dated on 2016-07-28: 18 Biggest Mid-Day Losers For Thursday

Financial news for ARGs dated on 2016-07-28: 16 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARGs dated on 2016-07-27: After-Hours Losers Jul. 27, '16: INFN Down 29%, ARGs 17.7%, RCIH 14.4%, IVTY 11.2%, RRTS 11%, KONA 9.8%, MMLP 8.4%, ECHO 8.3%, TER 7.8%

Financial news for ARGs dated on 2016-07-27: Beyond Earnings: 10 Stocks Moving In Wednesday's After-Hours Session

Financial news for ARGs dated on 2016-07-27: Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Financial news for ARGs dated on 2016-07-27: Argos Therapeutics Announces Public Offering Of Common Stock

Financial news for ARGs dated on 2016-07-22: Argos Therapeutics Filing Shows Shareholders Seeking To Offer Up To 19.5M Shares

Financial news for ARGs dated on 2016-07-14: Argos Therapeutics Reports Initial Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV

Financial news for ARGs dated on 2016-07-11: Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer

Financial news for ARGs dated on 2016-06-15: Argos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies For Argos' Investigational Immunotherapies

Financial news for ARGs dated on 2016-06-13: Mid-Afternoon Market Update: Dow Falls 75 Points; Eleven Biotherapeutics Shares Spike Higher

Financial news for ARGs dated on 2016-06-13: 7 Biggest Mid-Day Losers For Monday

Financial news for ARGs dated on 2016-05-11: Argos Therapeutics to Participate in World Stem Cells and Regenerative Medicine Congress On May 18-20, 2016

Financial news for ARGs dated on 2016-04-20: Mid-Afternoon Market Update: Dow Rises 0.5%; Argos Therapeutics Shares Drop

Financial news for ARGs dated on 2016-04-20: Mid-Afternoon Market Update: Dow Up 0.5%; Argos Therapeutics Shares Drop

Financial news for ARGs dated on 2016-04-20: Mid-Day Market Update: VMware Surges On Earnings Beat; Flexsteel Shares Tumble

Financial news for ARGs dated on 2016-04-20: Mid-Morning Market Update: Markets

Mostly Flat; Coca-Cola Earnings Top Expectations

Financial news for ARGS dated on 2016-04-19: Argos Therapeutics To Reduce Workforce By 13%, COO Fred Miesowicz To Resign; Will Incur \$400K One Time Charge For Reduction

Financial news for ARGS dated on 2016-04-19: Roth Capital Maintains Buy on Argos Therapeutics, Raises PT to \$18.00

Financial news for ARGS dated on 2016-04-19: Roth Capital Maintains Buy on Argos Therapeutics, Raises PT to \$18.00

Financial news for ARGS dated on 2016-03-30: Mid-Afternoon Market Update: FormFactor Drops On Weak Forecast; ConforMIS Shares Gain

Financial news for ARGS dated on 2016-03-30: Mid-Day Market Update: ACADIA Pharmaceuticals Rises Following FDA Panel Vote; Verint Systems Shares Slide

Financial news for ARGS dated on 2016-03-29: Argos Therapeutics Reports Q4 EPS \$(0.84) vs. Est. \$(0.88)

Financial news for ARGS dated on 2016-03-23: Argos Therapeutics Reports Initiation of Phase 2 Trial of AGS-003 for Treatment of Non-Small Cell Lung Cancer in Combo with Standard of Care Chemo

Financial news for ARGS dated on 2016-03-07: Argos Therapeutics Reports \$60M Financing

Financial news for ARGS dated on 2016-03-07: Argos Therapeutics Announces Financing of Up to \$60M To Fund Ops Through Q2 2017

Financial news for ARGS dated on 2016-01-20: Argos Therapeutics Names Dr. Lee Allen Chief Medical Officer

Financial news for ARGS dated on 2015-12-10: Independent Data Monitoring Committee Recommends Continuation of Argos Therapeutics ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following 2nd Interim Analysis

Financial news for ARGS dated on 2015-11-16: Stocks Hitting 52-Week Lows

Financial news for ARGS dated on 2015-11-16: Morning Market Losers

Financial news for ARGS dated on 2015-11-16: Argos Therapeutics Reports Q3 EPS \$(0.97) vs Est \$(0.92), Sales \$158.349K Vs Est \$230.00K

Financial news for ARGS dated on 2015-09-04: Argos Therapeutics Director Van Holle Buys 12,000 Shares @\$6.27/Share -Form 4

Financial news for ARGS dated on 2015-08-26: Argos Therapeutics Director Lamarre Buys 2,500 Shares @\$6.14/Share -Form 4

Financial news for ARGS dated on 2015-08-24: Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection

Financial news for ARGS dated on 2015-08-12: Argos Therapeutics Reports Q2 Loss \$0.95 vs Est Loss \$0.80, Revs \$107.391K vs Est \$700.00K

Financial news for ARGS dated on 2015-08-10: Argos Therapeutics Reports Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma

Financial news for ARGS dated on 2015-07-17: Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Financial news for ARGS dated on 2015-07-15: Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003

Financial news for ARGS dated on 2015-06-04: Independent Data Monitoring Committee Recommends Continuation of Important ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma

Financial news for ARGS dated on 2015-05-29: Argos Therapeutics to Present at the Annual Sachs Immuno-Oncology: BD&L and Investment Forum

Financial news for ARGS dated on 2015-05-14: Argos Therapeutics Reports Q1 Loss of \$0.89/Share vs Loss of \$0.80/Share Est., Sales \$178.77K vs \$270K Est.

Financial news for ARGS dated on 2015-05-13: Argos Therapeutics Gives Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial

Financial news for ARGS dated on 2015-05-08: Argo Therapeutics Reports \$125M Mixed Shelf Filing

Financial news for ARGS dated on 2015-04-21: Argos Therapeutics Reports Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma

Financial news for ARGS dated on 2015-04-20: Argos Therapeutics to Present Update on Important Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting

Financial news for ARGS dated on 2015-04-14: Argos Therapeutics Licenses Arcelis(R) Technology Platform to Lummy HK for Development of Personalized Immunotherapies to Treat Cancer in China

Financial news for ARGS dated on 2015-04-13: 8-K from Argos Therapeutics Shows License Deal with Unit of Lummy, Co. Could Receive Up to \$20M

Financial news for ARGS dated on 2015-03-30: Argos Therapeutics Reports Q4 EPS -\$0.83 Vs Est -\$0.73, Sales \$0.3M vs Est \$0.67M

Financial news for ARGS dated on 2015-03-26: Roth Capital Initiates Coverage on Argos Therapeutics at Buy, Announces \$21.00 PT

Financial news for ARGS dated on 2015-02-27: Argos Therapeutics Announces Update on Phase 3 ADAPT Trial at ASCO Genitourinary Cancers Symposium

Financial news for ARGS dated on 2015-02-25: MLV & Co. Initiates Coverage on Argos Therapeutics at Buy

Financial news for ARGS dated on 2015-01-09: Morning Market Losers

Financial news for ARGS dated on 2015-01-09: Argos Thera Says Phase 2 Trial Did Not Meet Endpoints

Financial news for ARGS dated on 2015-01-09: Argos Therapeutics Halted News Pending

Financial news for ARGS dated on 2015-01-06: Argos Therapeutics and Saint-Gobain Announce Agreement for Production of Disposables Used in Automated Manufacturing of Fully Personalized Immunotherapies

Financial news for ARGS dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for ARGS dated on 2014-11-13: Argos Therapeutics Reports Q3 EPS of \$(0.77) vs \$(0.55) Est; Revenue of \$398.62K vs \$1.03M Est

Financial news for ARGS dated on 2014-11-13: 1 Way To Search For The 'Next Big Thing' In Biotech

Financial news for ARGS dated on 2014-11-05: Invetech And Argos Therapeutics Announce Agreement To Support Global Production Of Fully Personalized Immunotherapies

Financial news for ARGS dated on 2014-11-04: Argos Therapeutics Enters Amended Development Pact With Investech

Financial news for ARGS dated on 2014-10-22: Argos Therapeutics Breaks Ground On State-of-the-Art Biomanufacturing Facility In Research Triangle Park Area

Financial news for ARGS dated on 2014-09-30: Argos Therapeutics Enters Into \$25M Venture Loan Facility

Financial news for ARGS dated on 2014-09-18: Enrollment In Argos Therapeutics' Pivotal Phase III ADAPT Trial of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent

Financial news for ARGS dated on 2014-09-08: Argos Announces Issuance Of Arcelis Technology Patent

Financial news for ARGS dated on 2014-08-13: Argos Therapeutics Reports Q2 EPS of \$(0.61) Which May Not Compare \$(0.60) Est; Revenue of \$473.0K Which May Not Compare \$1.27M Est

Financial news for ARGS dated on 2014-06-02: Argos Announces Moderate Results For AGS-003

Financial news for ARGS dated on 2014-05-13: Argos Therapeutics Reports Q1 EPS of \$(1.05) vs \$(0.46) Est; Revenue of \$798.79K vs \$1.26M Est

Financial news for ARGS dated on 2014-05-12: Argos to Present AGS-003 Data During

2014 ASCO Annual Meeting

Financial news for ARGs dated on 2014-03-31: Argos Therapeutics Added to Russell 2000(R) and 3000(R) Indexes

Financial news for ARGs dated on 2014-03-04: UPDATE: Stifel Initiates Coverage on Argos Therapeutics on Positive Outlook

Financial news for ARGs dated on 2014-03-04: Benzinga's Top Initiations

Financial news for ARGs dated on 2014-03-04: Stifel Nicolaus Initiates Coverage on Argos Therapeutics at Buy, Announces \$16.00 PT

Financial news for ARGs dated on 2014-02-07: Shares of Argos Therapeutics Open for Trade at \$8.90 After Pricing at \$8/Share

Financial news for ARGs dated on 2014-02-07: Waiting on IPO Open in Argos Therapeutics, Quotes Will Open at 10:10, Expected to Open for Trade at 10:25AM EST, Priced 5.625M Shares at \$8/Share